Anavex Life Sciences

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Anavex Life Sciences reports Q1 results, highlights precision medicine focus

Anavex Life Sciences showcased positive results in the Alzheimer's study and emphasized precision medicine in addressing neurological disorders.
The company's financial performance, with a net loss of $13 million and a cash position of $143.6 million, reflects ongoing research and development efforts.
Challenges include financial losses, regulatory discussions, and operational complexities, while opportunities lie in upcoming data readouts and new clinical trials.
Overall, Anavex's strategic focus on precision medicine and diverse pipeline position it for potential growth and advancements in neurological treatments.

Anavex Life Sciences reports Q2 results, eyes pipeline expansion

Anavex Life Sciences reported a mixed financial performance in Q2 2023 but maintains a strong cash position for future operations and clinical programs.
The company's focus on Alzheimer's disease treatments, pipeline expansion, and team strengthening reflect a commitment to advancing innovative therapies.
While facing financial challenges and competitive pressures, Anavex has opportunities to leverage its clinical successes, new hires, and partnerships for future growth.

Anavex Life Sciences reports Q3 loss, eyes neurology breakthroughs

Anavex Life Sciences is actively pursuing clinical advancements in neurology with a focus on blarcamesine. Despite financial challenges, the company's strategic partnerships and pipeline expansion position it well for future growth and innovation.

Anavex Life Sciences reports strong cash position amidst strategic focus

Anavex Life Sciences demonstrated financial strength with a substantial cash position in Q4 2023, while facing challenges with a net loss.
The company's strategic focus on precision medicine programs and ongoing trials presents opportunities for growth and innovation in the healthcare sector.
Navigating regulatory processes and balancing financial sustainability will be key for Anavex to capitalize on its strengths and address operational challenges.

Anavex Life Sciences reports Q1 loss but advances precision medicine

Anavex Life Sciences reported financials reflecting a net loss but with a solid cash position, emphasizing fiscal responsibility and ongoing research progress.
The company's strengths lie in its financial stability, innovative precision medicine focus, and commitment to addressing neurological disorders.
Challenges include managing financial losses, meeting regulatory timelines, and balancing fiscal prudence with research investments.
Opportunities arise from upcoming submissions, precision medicine trends, therapeutic expansion, and potential collaborations.

Anavex Life Sciences reports Q2 progress amidst analyst inquiries

Anavex Life Sciences is actively pursuing the development of therapies for various neurological disorders. The company faces challenges in FDA guidance interpretation, European filings, and commercialization strategies. However, with a solid cash position and a focus on transformative therapies, Anavex has significant growth opportunities.

Anavex Life Sciences reports Q3 results, advances precision medicine

Anavex Life Sciences showcased financial stability with a strong cash position despite reporting a net loss, underlining their commitment to advancing treatments for brain disorders.
Progress in trials for blarcamesine in Alzheimer's disease and other neurological conditions signals potential breakthroughs in precision medicine.
While facing challenges such as managing losses and regulatory uncertainties, Anavex remains poised to leverage opportunities through upcoming data releases and regulatory submissions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will join a panel discussion titled, “Fragile X Syndrome Case Study: From Preclinical to Clinical, Making Drug Development Efficient through Community-based Collaboration” at the 5th Pharma Pricing, Reimbursement & Market Access 2021 conference on Wednesday, September 29th at 2:40 pm ET.

Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021

NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that effective as of market open today, September 27, 2021, its shares of common stock have been approved for uplisting to the NASDAQ Global Select Market® and will continue trading under its current ticker symbol AVXL.

Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market®

NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 10:40 AM (ET). The conference is being held September 27-30, 2021.

Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference

Lead candidate ANAVEX2-73 has shown impressive results in placebo-controlled Phase 2 studies in Parkinson's disease and Rett syndrome. Ongoing studies in Rett syndrome could lead to a filing in 2022 if results are positive.

Anavex Life Sciences: Still Room To Run

Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q3 2021 Results - Earnings Call Transcript

NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended June 30, 2021.

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results

Annovis Bio

Cassava Sciences Inc

Millions of Americans are struggling with Alzheimer's, according to the Alzheimer's Association. The disease often has a slow progression, lasting years or even decades, and it's one of the leading causes of death in the United States.

Use Weakness in these 3 Alzheimer's Disease Stocks as Opportunity

NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat in the BTIG Virtual Biotechnology Conference 2021 on Tuesday, August 10, 2021 at 9:30 a.m. EDT.

Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021

Biogen

Biogen's Aduhelm performed no better than placebo in non-ApoE4 carriers and only slightly slowed down the progression of Alzheimer's disease in ApoE4 carriers.

Detours In The Golden Age Of Alzheimer's Drug Stock Investments

A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.

Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday

Anavex Life Sciences Corp (NASDAQ: AVXL) has reported new preclinical data for its Alzheimer's candidate, ANAVEX2-73 (blarcamesine). Pre-treatment with blarcamesine repeated once daily for one week before the Aβ (Abeta) challenge was protective in the Aβ25-35 peptide model of Alzheimer's mice model.

Anavex Life's Stock Declines Despite Data Shows Alzheimer's Candidate Prevent Abeta-Induced Cognitive Decline In Animal Study

On Anavex's (AVXL) earnings call for the fiscal third quarter, investor focus will mainly be on the company's progress with its lead investigational candidate for Alzheimer's disease.

Anavex (AVXL) to Report Q3 Earning: What's in the Cards?

GT Biopharma Inc

Are biotech penny stocks on your watch list in 2021? The post 3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021

Anavex Life Sciences Corporation conducts clinical trials for its small Anavex 2-73 (blarcamesine) and Anavex 3-71 (AF710B) molecules. The biotech has a rich development pipeline aimed at neurodegenerative and neuro-developmental disorders, such as Parkinson's, Alzheimer's and Rett diseases.

Anavex: A Catalyst-Rich Year

A Cantor Fitzgerald analyst is incrementally bullish on shares of Anavex Life Sciences, Corp (NASDAQ:AVXL) after the release of Phase 2 data for the company's lead candidate. The Anavex Analyst: Charles Duncan, Ph.D.

Why This Anavex Life Sciences Analyst Is Lifting Their Price Target

The stock price of Anavex Life Sciences Corp (NASDAQ: AVXL) increased by over 15% during intraday trading. This is why it happened.

AVXL Stock Price Increases Over 15%: Why It Happened

Anavex Life Sciences Corp. (NASDAQ: AVXL) shares traded higher Monday after the company announced ANAVEX2-73, the company's main pipeline drug, improved both primary cognitive and secondary MDS-UPDRS efficacy endpoints with significant biomarker correlation in placebo-controlled Phase 2 clinical trial for treatment of Parkinson's disease.  Anavex Life Sciences was up 18.37% at $29.30 at last check.

Anavex Life Sciences Stock Rallies: Technical Levels To Watch

Bionano Genomics

MannKind

Mogo

Qumu Corp.

Comscore Inc.

Current & Former Penny Stocks With High Marks From Analysts Right Now. The post 7 Hot Penny Stocks Analysts Like To Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks Analysts Like To Watch In 2021

The biopharma developer dropped some big (but mostly expected) news about the success of one of its drugs.

Why Anavex Life Sciences Shares Are Up 17% Today

Anavex Life Sciences Corp (NASDAQ: AVXL) has reported that SIGMAR1 mRNA expression correlates positively with responses in efficacy endpoints in the Phase 2 trial of ANAVEX 2-73 (blarcamesine) in patients with Parkinson's disease dementia. ANAVEX 2-73 activates the sigma-1 receptor (SIGMAR1), restoring neural cell homeostasis and promoting neuroplasticity.

Anavex Life Sciences Stock Jumps As Blarcamesine Shows Convincing Biomarker-Correlating Efficacy Data In Parkinson's Disease, Dementia Patients

NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced the closing of its previously announced registered direct offering to Deep Track Capital for the issuance and sale of an aggregate of 2,380,953 shares of its common stock at a purchase price of $21.00 per share of common stock. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering

The stock price of Anavex Life Sciences Corp (NASDAQ: AVXL) fell by over 5% pre-market. This is why it happened.

AVXL Stock Price Falls Over 5% Pre-Market: Why It Happened

The good news keeps coming for one of the biotech's pipeline drugs.

Why Anavex Life Sciences Blasted Higher Today

Anavex Life Sciences Corp (NASDAQ: AVXL) has reported a predictive biomarker response from its Phase 2 trial of ANAVEX2-73 (blarcamesine) in adult female patients with Rett syndrome. Data showed that ANAVEX2-73 treatment resulted in a significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the two primary clinical efficacy endpoints - Rett Syndrome Behaviour Questionnaire (RSBQ) and CGI-I (assessment scale for determining the effects of mental health treatment)

Anavex Life's Rett Syndrome Candidate Shows Promising Biomarker Correlating Efficacy Data

The stock price of Anavex Life Sciences Corp (NASDAQ: AVXL) increased by over 10% pre-market. This is why it happened.

News for Anavex Life Sciences Stock (AVXL)